|Mr. Kenneth L. Londoner M.B.A., MBA||Founder, CEO & Exec. Chairman||1.2M||N/A||1968|
|Mr. Steven Chaussy||Chief Financial Officer||N/A||N/A||1954|
|Dr. Budimir S. Drakulic Ph.D.||Chief Scientist||N/A||N/A||1950|
|Ms. Lora Mikolaitis||VP of Admin.||N/A||N/A||1973|
|Mr. Andrew Gornell Ballou||VP of Investor Relations||N/A||N/A||N/A|
|Mr. John M. Kowalski||VP of Sales||N/A||N/A||N/A|
|Mr. Olivier Chaudoir||Sr. Director of Marketing||N/A||N/A||N/A|
|Ms. Brenda Castrodad||Director of HR||N/A||N/A||N/A|
|Ms. Natasha Drapeau||Exec. VP||N/A||N/A||N/A|
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation and ventricular tachycardia. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
BioSig Technologies, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 7; Compensation: 10.